Novartis CEO sees chance to accelerate profit margin target


PHOTO FILE: CEO Vas Narasimhan of Swiss drugmaker Novel, Switzerland January 30, 2019. REUTERS / Arnd Wiegmann

ZURICH (Reuters) – Novartis could be a big business business. T “a little sooner” until 2022, as it now forecasts,

35%, ”They said to her. event. “That could happen a little sooner, we see it on how the launches go. If they did (better launch), I think we would get there sooner.

The first year of the year, from 31.3% of sales, from 31.3% of sales, from 31.3% of sales

Reporting by John Miller; Editing by Michael Shields

Our Standards:The Thomson Reuters Trust Principles.

(tagsToTranslate) US (t) NOVARTIS (t) INVESTORS (t) MARGIN (t) Results Forecasts / Warnings (t) Mergers / Acquisitions / Takeovers (t) Switzerland (t) China (PRC) (t) Pharmaceuticals (TRBC) (t) Asia / Pacific (t) Europe (t) Pharmaceuticals and Medical Research (TRBC) (t) Healthcare (TRBC)


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.